Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Herpes Zoster (Shingles) Pipeline Review 2016 - Research and Markets

Research and Markets
Posted on: 27 Oct 16

Research and Markets has announced the addition of the "Herpes Zoster (Shingles) - Pipeline Review, H2 2016" report to their offering.

Herpes Zoster (Shingles) pipeline therapeutics constitutes close to 15 molecules. Out of which approximately 15 molecules are developed by Companies. The molecules developed by Companies in Phase III, Phase II, Preclinical and Unknown stages are 4, 2, 7 and 2 respectively.

Herpes Zoster (Shingles) - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Herpes Zoster (Shingles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Herpes Zoster Overview
  3. Therapeutics Development
  4. Pipeline Products for Herpes Zoster - Overview
  5. Pipeline Products for Herpes Zoster - Comparative Analysis
  6. Herpes Zoster - Therapeutics under Development by Companies
  7. Herpes Zoster - Therapeutics under Investigation by Universities/Institutes
  8. Herpes Zoster Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Herpes Zoster - Products under Development by Companies
  13. Herpes Zoster - Products under Investigation by Universities/Institutes
  14. Herpes Zoster - Companies Involved in Therapeutics Development
  • Astellas Pharma Inc.
  • Beijing Minhai Biotechnology Co., Ltd
  • ContraVir Pharmaceuticals, Inc.
  • Epiphany Biosciences, Inc.
  • Foamix Pharmaceuticals Ltd.
  • GeneOne Life Science, Inc.
  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • N & N Pharmaceuticals Inc.
  • NAL Pharmaceuticals Ltd.
  • NanoViricides, Inc.
  • ReceptoPharm, Inc.
  • TSRL, Inc.
  • XBiotech Inc

For more information about this report visit

View source version on

Business Wire

Last updated on: 27/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.